ResearchBib Share Your Research, Maximize Your Social Impacts
Sign for Notice Everyday Sign up >> Login

Diabetes and the Younger/Middle-Aged Hypertensive Subject; Obesity, Sympathetic Nerve Activity and Treatment Implications

Journal: Journal of Diabetes Research and Therapy (Vol.3, No. 1)

Publication Date:

Authors : ;

Page : 1-8

Keywords : Diabetes; Hypertension; Sympathetic nerve activity;

Source : Downloadexternal Find it from : Google Scholarexternal

Abstract

Summary and conclusion There is an obesity/type-2 diabetes/hypertension epidemic in developed countries around the world. Central obesity is closely linked to hypertension and type-2 diabetes in young/middle-age. In this younger, probably obese, age-group diastolic hypertension is linked to increased sympathetic nerve activity (via raised plasma insulin and leptin levels acting upon the hypothalamic region), particularly in the presence of type-2 diabetes. Chronically raised sympathetic nerve activity and beta-receptor levels (in lymphocytes), independent of blood pressure, are powerful predictors of myocardial infarction in the middle-aged. This has treatment implications for the young/middle-aged hypertensive subjects, with or without type-2 diabetes. Antihypertensive agents that increase sympathetic nerve activity e.g. dihydropyridine calcium blockers, thiazide-type diuretics, and angiotensin receptor blockers, do not reduce (and may increase) the risk of myocardial infarction in the younger/middle-aged hypertensive subject. Beta- 1 blockade, effective in reversing and stabilizing coronary atheromataous plaque, is at least as good as ACE-inhibition in preventing hard cardiovascular endpoints (including myocardial infarction, and is significantly superior in preventing all-cause death). Thus, beta-1 blockade is a highly reasonable first-line treatment in young/middle-aged hypertension with or without type-2 diabetes.

Last modified: 2020-08-11 23:02:13